Tumor-associated antigen presentation via major histocompatibility complex class I and II on dendritic cell (null)

Tumor-associated antigen presentation via major histocompatibility complex class I/II on dendritic cells is the process whereby dendritic cells acquire, process, and present peptides derived from tumor antigens to T cells. MHC class I on dendritic cells presents antigens to CD8+ cytotoxic T lymphocytes—critical for killing tumor cells via cross-presentation. MHC class II proteins present antigens to CD4+ helper T cells, orchestrating broader immune responses and supporting cytotoxic T cell activity. This process is central to cancer immunosurveillance, dendritic cell vaccine development, and immune therapies for cancer. However, its effectiveness is limited by tumor-induced DC dysfunction, immune evasion, and the risk of autoimmunity when immune activation is excessive or misdirected. Key molecules in this process include the MHC class I and II proteins themselves, dendritic cell surface markers, and numerous intracellular antigen-processing and trafficking proteins. The process relies on DC functional states and is shaped by the tumor microenvironment. Drugs and immunotherapies that harness or modulate this process are in development, primarily aiming to boost antitumor T cell responses or reverse tumor-induced immune suppression.

Other names

Antigen presentation by dendritic cellsTumor antigen cross-presentationDC-mediated tumor antigen presentationCross-priming (for some contexts)

Enhancement of tumor antigen uptake and presentation by dendritic cells; Activation of T cells via presented tumor antigens; Immune stimulation (with adjuvants or cytokines); Modulation of dendritic cell maturation and function